Solid Biosciences LLC (SLDB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.91 (+0.45%), Market cap $0.76B, 52-week low–high $2.55 ~ $8.63.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations
Financial statements, price targets, institutional (13F) holdings and related news for Solid Biosciences LLC are updated in real time on BlackAll Trade.
Solid Biosciences LLC trades at $8.91 (+0.45%). Real-time quotes and charts are available on BlackAll Trade.
Solid Biosciences LLC has a market cap of about $0.76B.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duche